We examined colorectal cancer (CRC) stage at presentation and mortality in a vulnerable population compared with nationally representative data.
Introduction
The Institute of Medicine defines safety-net providers as "providers that organize and deliver a significant level of health care and other related services to the uninsured, Medicaid, and other vulnerable populations" (1, 2) . Care delivery in the safety net is a significant challenge, as such systems simultaneously face financial challenges and resource limitations as they provide care to vulnerable populations (3) (4) (5) (6) . Furthermore, vulnerable populations are more likely to suffer from complex medical conditions because of socioeconomic factors (7) . One area that deserves further attention is the pattern of colorectal cancer (CRC) presentation in the safety net. Specifically, we focused on CRC presentation and survival outcomes.
CRC is the third most common malignancy and the second leading cause of cancer death among men and women in the United States (8) . Despite evidence that has shown that CRC screening is effective in reducing CRC mortality (9) (10) (11) , CRC screening is underutilized by the general population and even more so among minority populations and in the safety net (12) (13) (14) . Patterns and outcomes of CRC care in the safety net are worth examining given that the very tools that allow safety-net hospitals to care for patients, such as culturally competent programs, can strengthen the quality of care given to patients (15, 16) .
The objective of this study was to examine CRC stage at presentation and mortality in the safety net compared with nationally representative data. Compared with nationally representative data, we hypothesized that in the safety net, the spectrum of disease stage is weighted toward advanced disease, probably because of both low exposure to screening and late utilization of medical care.
Methods
Study population. Consecutive patients diagnosed with CRC were identified at San Francisco General Hospital (SFGH) between 1996 and 2009. SFGH is the safety-net hospital for the residents of San Francisco. According to the 2010 US Census, the population of San Francisco was 805,235 people (17) . SFGH serves approximately
The red secTion 467 100,000 patients per year, the majority of whom are non-white. The hospital's patient population is racially and ethnically diverse: 24% white, 30% Hispanic, 18% black, and 23% Asian (18) . In 2009-2010, 79% of inpatients and 64% of outpatients were either uninsured or covered by Medi-Cal, California's state health program for lowincome and resource-limited residents (18, 19) .
To compare our safety-net population data with nationally representative data, we obtained cancer surveillance data from the Surveillance Epidemiology and End Results (SEER) program. The SEER program of the National Cancer Institute collects information on cancer incidence and survival from population-based cancer registries. It covers approximately 28% of the US population and serves as the comprehensive source of population-based information on stage at cancer diagnosis and survival data (20) . Mortality data linked to SEER are provided by the National Center for Health Statistics (20, 21 (22) . For mortality data, we used SFGH medical records, which are linked to the California death registry. In addition, we searched the Social Security Death Index to capture those not recorded within the California death registry.
In addition to CRC-specific data, we also collected data on exposure to CRC screening. At SFGH, fecal occult blood testing is the primary CRC screening modality, and colonoscopy is offered to those with positive occult blood tests or at high risk for developing CRC. We limited our analysis of patient utilization of CRC screening to patients who had received care at SFGH for at least 1 year. These established patients would have had an opportunity to utilize screening tests. Conversely, those diagnosed with CRC within the year of establishing care at SFGH were more likely to be symptomatic, which could confound the indication for testing.
From the SEER registry, we identified CRC cases using colon and rectum site codes (adolescent and young adult (AYA) site recode 8.6.1) during the same time period. Patients with histological codes for carcinoma in situ were excluded. We extracted race/ethnicity, sex, age at diagnosis, presence of surgical resection, and American Joint Committee on Cancer stage at diagnosis during the same time period. Of 308,131 cases identified, 32,848 were dropped because they had carcinoma in situ or unknown stage at diagnosis. Statistical analysis. Patient demographics were compared between the SFGH and SEER cohorts using t-and c 2 tests as appropriate. We used a multinomial model to assess between-cohort differences in stage at presentation, after exploratory analyses using the simpler proportional odds model revealed violations of the proportional odds assumption. We also used a logistic model to compare presentation at stages 3 and 4. In all these analyses we adjusted for age, sex, and race and also assessed effect modification by these covariates, using Wald c 2 tests for interaction. We then used Cox models to compare survival after CRC diagnosis in the SFGH and SEER cohorts, adjusting for age, sex, race, and stage at presentation. Tests for effect modification indicated heterogeneity by race (P = 0.002). We then used Kaplan-Meier curves to characterize survival in the SFGH and SEER cohorts, stratified by race, and adjusting for age, sex, and stage at diagnosis. We also used Cox models and adjusted Kaplan-Meier curves to assess differences by race within the SFGH cohort, adjusting for age, sex, and stage at presentation. We determined the proportion of people in the SFGH cohort who utilized CRC screening. Exposure to any CRC screening test was determined among the people who had established care for longer than 1 year. We chose to restrict this analysis because, though a person may have screened positive for CRC within the year of diagnosis, symptoms such as anemia, hematochezia, and changes in bowel habits secondary to the CRC may have confounded the indication for testing.
Stata, version 11 (Stata, College Station, TX), was used for all analyses. This study was approved by the committee on human research at the University of California, San Francisco (approval no. 10-01423).
Results

Patient characteristics.
We identified 289 white, black, Asian, and Hispanic patients with stages 1-4 CRC in the SFGH cohort and 272,857 cases in the SEER cohort; 2,426 additional CRC patients classified by SEER as "other" race were omitted from the analysis. As shown in Table 1 , CRC patients at SFGH were younger (58 vs. 69 years), more likely to be male (57% vs. 51%), and more racially diverse (SFGH: 20% white, 22% Hispanic, 39% Asian, 19% black; SEER: 76% white, 8% Hispanic, 7% Asian, 9% black).
Stage at presentation.
Relative to presentation at stage 1, SFGH patients had roughly twofold increased risk, compared with SEER patients, of presenting at stage 2, 3, or 4 (overall P = 0.001), after adjustment for age, sex, and race ( Table 2) . SFGH patients were also more likely to present at stage 3 or 4 (adjusted odds ratio 1.28, 95% confidence interval (CI) 1.01-1.61, P = 0.04). Although the test for interaction between cohort and race was not statistically significant (P = 0.29), later stage at presentation at SFGH compared with SEER was most evident among blacks (adjusted odds ratio 1.80, 95% CI 1.02-3.17, P = 0.04) and Asians (adjusted odds ratio 1.41, 95% CI 0.97-2.05, P = 0.07). Specifically, the proportion of advanced-stage CRC within SFGH was 50% in whites, 46% in Hispanics, 58% in Asians, and 67% in blacks.
Survival. In Cox models comparing SFGH with SEER patients, we found weak evidence for increased mortality risk in SFGH overall (adjusted hazard ratio (aHR) 1.19, 95% CI 0.98-1.44, P = 0.08). However, this effect varied by race (P = 0.002), with poorer survival in SFGH patients, compared with SEER, among whites (aHR 2.13, 95% CI 1.51-3.02, P < 0.001; Figure 1a ) and possibly blacks (aHR 1.38, 95% CI 0.95-2.01, P = 0.09; Figure 1d ), but some evidence for better survival among Asians (aHR 0.77, 95% CI 0.53-1.12, P = 0.17; Figure 1c) .
In comparisons within SFGH, mortality risk was lower among Asians than among whites (aHR 0.35, 95% CI 0.21-0.59, P < 0.001) and blacks (aHR 0.39, 95% CI 0.23-0.68, P = 0.001) (Figure 2 ). Hispanics were also at lower risk than whites (aHR 0.45, 95% CI 0.25-0.81, P = 0.008) and blacks (0.51, 95% CI 0.27-0.94, P = 0.03) but comparable to Asians (aHR 1.28, 95% CI 0.70-2.34, P = 0.42). 
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Utilization of health-care services. We also examined the utilization of health-care services, including screening and surgical resection. Of the SFGH cohort, 44% had a diagnosis of CRC within 1 year of establishing care at SFGH. Of the remaining 56% who had been SFGH patients for at least 1 year, only 22% had any exposure to CRC screening tests. Of those patients, 27 had fecal occult blood testing, 4 underwent colonoscopy, and 4 underwent sigmoidoscopy. With regard to surgical resection, there was no statistically significant difference in resection rates between SFGH (87.5%) and SEER (90.4%). There was also no statistically significant difference in the resection rates by race in the SFGH cohort. The resection rate was highest at 90% among Asians and Hispanics and lowest at 83% among whites and blacks (P = 0.33).
Discussion
In this study comparing history of screening, stage at presentation, and mortality among CRC cases at SFGH, a safety-net hospital, vs. CRC cases reported to the nationally representative SEER cancer registry, we found that a somewhat greater proportion presented at an advanced stage at SFGH. The screening rates among SFGH patients with at least 1 year of care were low and may have contributed to late stage at presentation. Survival was also nominally shorter among SFGH patients overall, compared with SEER, but the differences varied by race. At SFGH, survival was clearly longer among Asians, compared with whites, blacks, and Hispanics; there was also weak evidence that their mortality risk was lower than that of Asians in SEER, despite nominally increased risk of presenting at stage 3 or 4. These findings may help us to understand racial disparities in CRC screening and presentation at a safety-net hospital, and to identify potential interventions to address them. Such racial disparities in CRC, specifically late stage at presentation and higher mortality rates, have been well documented in the black population (23) (24) (25) (26) . While socioeconomic and biological factors may play a role, lack of participation in CRC screening has been documented and is a modifiable factor (23, (26) (27) (28) . One study showed that blacks may be less likely than whites to undergo colonoscopy even after an abnormal sigmoidoscopy (29) . Blacks, then, tend to receive less screening and present with more advanced stage of disease (23, 27) . Other studies have identified knowledge gaps and competing priorities as potential barriers to CRC care among blacks (30) (31) (32) (33) . Our observation that Asians also present disproportionately late, similarly to blacks, suggests that similar challenges in either access or utilization of CRC screening services may exist.
While CRC screening tests are available at SFGH, utilizing such tests involves access to a primary-care physician. In this study population, almost half (44%) of the patients presented to the safety net for care within the year of their CRC presentation, suggesting that many patients may access the system only after they become symptomatic. Therefore, solutions are necessary to reach a population of vulnerable, often uninsured or underinsured patients before the development of cancer. These solutions include culturally competent care, community education, and outreach.
For patients with access to a primary-care physician, low adherence to CRC screening may be a result of many factors, including differences in health beliefs or patient and provider knowledge gaps (34) . We have shown, however, that with appropriate infrastructure to facilitate screening, this vulnerable population will complete CRC screening at rates approaching 70% (34) . While the exact reasons for late disease presentation and low utilization of screening tests are beyond the scope of this work, a better understanding of health beliefs and competing demands for each individual person may be important to bridge the divide between resource availability and a patient's access to and utilization of those resources.
Our study has several important limitations. First, we did not have access to screening-utilization data among all patients cared for at SFGH. Therefore, although we examined the utilization rates among those with CRC, we cannot generalize these results to utilization of CRC services by the entire safety-net population. Second, SFGH is only one safety-net system. But like many other safety nets, SFGH provides care to a diverse and underserved population. SFGH therefore serves as a model for understanding opportunities to improve health-care delivery to a challenging population.
In summary, our study shows that despite generally broad access to care at the safety-net hospital in San Francisco, patients 
